The Novavax coronavirus vaccine might be cleared by regulators to be used in a number of international locations, together with the U.S., within the coming months, the vaccine-maker’s CEO mentioned Monday.
The corporate has filed for emergency approval with 10 completely different regulatory businesses, Stanley Erck instructed CNBC’s “Squawk on the Road.” It is at the moment accessible to be used in 170 international locations, he mentioned.
“I count on within the subsequent 90-days we might have all 10 of them,” Erck mentioned.
The corporate submitted its ultimate information to the U.S. Meals and Drug Administration on New 12 months’s Eve. It’s nonetheless gearing as much as file the total software for emergency use authorization, however it’s going to achieve this shortly and expects a call from American regulators to return in February, he mentioned.
A girl holds a small bottle labeled with a “Coronavirus COVID-19 Vaccine” sticker and a medical syringe in entrance of displayed Novavax brand on this illustration taken, October 30, 2020.
Dado Ruvic | Reuters
Erck did not title the opposite regulatory businesses it submitted requests to. According to the company’s site, it has just lately utilized for approval in Japan, the United Arab Emirates, Singapore, New Zealand, Canada, Australia, South Africa and the UK.
A number of different well being businesses throughout the globe have already given their nod of approval to the vaccine.
Novavax just lately shipped its first doses of the vaccine to Europe, Erck mentioned. It had been approved by European Union regulators final month.
“All the things is coming collectively,” Erck instructed CNBC.
The vaccine might be in excessive demand. Novavax’s vaccine is protein primarily based, utilizing an alternate know-how to the extra widespread mRNA vaccines. That might assist in convincing individuals who had been skeptical of the brand new mRNA know-how to get vaccinated in opposition to the virus, Erck mentioned. It additionally appeared to have a considerably decrease charge of antagonistic facet impacts, in comparison with different vaccines.